{"name":"Triveni Bio","slug":"triveni-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOV0RaUmM3ZWdQcUlzZUNlUTVZT3VXUFVRQ0pyekMyTy1HQXlCOEtjUzZXMi1fUW9vX2xEN0pPUld4a2R5a1RRdHEtN2tRT1dkVWhDSGVLQXZRTFF5eVN3bk9zZHBKeUc2MzNKZ245Z1lFbmE3U2FtT1pEUjU2MHlpZ3FSMUpPQkJwakZHenVkbEFiRjVBNHVBMmNwbGQ3bC1WZ2JtQ1hKY0RlMDh6UFlWRDZkMHhUdVh6MWJuei1hT0RnZUNZbVZIXw?oc=5","date":"2026-03-23","type":"pipeline","source":"TipRanks","summary":"Triveni Bio Emphasizes Genetics-Informed Antibody Strategy in Autoimmune Diseases - TipRanks","headline":"Triveni Bio Emphasizes Genetics-Informed Antibody Strategy in Autoimmune Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQeTI4anY5bGVfTEtRYlJ2MzREb3JMRnBoUTB4NGV2MFN6LXlaSzhERlpjNTNGTEZialEyMi1CV2R4UmpSTXpkaUtpeE5OekJqd19SdDRYMy1xaDNWWFhaMW95ampvVjNCdFFaUUJ2VjlPWHhidDBoNl84aXlIeFBDcVhUN3gxNE9KbV9XSWRFcnowcXRGUTdlTU9qSl8wbVBpVnNxWUNJbE1iUFB1OF9xcVlYV3F0SUMzNWRxY2RMTk4zeTd1cnNNSDJn?oc=5","date":"2026-03-23","type":"pipeline","source":"TipRanks","summary":"Triveni Bio Highlights Genetics-Informed Antibody Strategy for Autoimmune Diseases - TipRanks","headline":"Triveni Bio Highlights Genetics-Informed Antibody Strategy for Autoimmune Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPd2FNcjJmS0tDM2FSSDBXdm5fRzdydFBMZlQwS2xWM2NUYnVybldydzd0WklJcmZGZDAycXFVaVBXYzg4MHpNeE9Hd0tpNVllTmZ3S296bzRXUkE1LTRfOVB5X29uTkIxVnpKLURtdkFWVk5OR0JKVUtGdUFETlRSdXlOYTduTmRxVW5XVW1NZ205MEJLV21YcWEyM1ZsMjlFRjlmbnE4RnV2THM?oc=5","date":"2026-01-14","type":"pipeline","source":"BioSpace","summary":"Adimab Records Another Year of Double-Digit Clinical Program Growth - BioSpace","headline":"Adimab Records Another Year of Double-Digit Clinical Program Growth","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"trial","source":"prnewswire.com","summary":"Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples ","headline":"Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZWZmdEYtVlVNbTdNM0dFcVhYWU1SUFdRak0xd3JfZlF6Vk1Td2lod2ZmOTVxYkdZNkFTUDE1RDRzbHNCcmJFTjAtNC1CVnJlWjV4enp6V2p6dGNTQmg4ajRBZUpWVXQweHhhV0dfVjJlWG1HZEFMY0hIQ2pFdzBocUE4d1JfOGZjaGpMbW1QVWRxdw?oc=5","date":"2025-09-22","type":"pipeline","source":"Fierce Biotech","summary":"Introducing Fierce Biotech's 2025 Fierce 15 - Fierce Biotech","headline":"Introducing Fierce Biotech's 2025 Fierce 15","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRElXUnJLRmVvUl82MjNva2J6UThYeVZwNzdBSmZvWHBScmttLXZKajY0aTE5cnk1UjNFb3FaSzBWTXpqOHk4ckdWLTVweGV0VVB6S3hOM2duY2hqblV5bGg2SDhBMGdZMzdMakdBeGVYWTBXNXVpczRNMDc5S3p6bDl5M3VwZC16S2hyLVVvY0taM0xfU0hWallqMEktTTdUSU5FVzc2ZVk?oc=5","date":"2025-08-26","type":"pipeline","source":"massbio.org","summary":"Massachusetts Biopharma Sees Rare Job Decline Amid Funding Constraints and Federal Uncertainty - massbio.org","headline":"Massachusetts Biopharma Sees Rare Job Decline Amid Funding Constraints and Federal Uncertainty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxQWTM1WERwekp0UloxT2VxZDJtX0xTd2UyQ2U0V0F5UlNZZ2NWZVJCOTJLeW9IZllvc3hYZk9jcnY5ZHlXZm1ZUGNvSlFVcml5SDlabzViWkh4WklRR2N3UUM3dEd5YmYwTlh0cmp2OFE0cXdkRUs5SXd1NTJNWFhWeHJ1eU5ZVjhXUWprTDNqRjNRM0VXeGVLUlpkVnRKOEg4R3c3czhaZUIwX2p0WE1zS0QxRGloNGZVZlRTZFFkNEFNY3lHVFNQbHNhRHJoWUtYaWFRV2RYNVYtd29LNjRRWmZqVTlDSDNZUHBJQmhxRGNPSzh4cVhHRzY5WDY3OXo4VVF3NEgyQ1cyVGdueDdneUdKZF9wbVUtcjdsRkVyQlFZSEZwblBkRHItY1c3UHYzX0xtNDI3NEV4Vmowb1k0dC1CYmFPMlpiWnFpOW1mS0dRR3ZyWG9fdXpzeGU4UWNXRUE?oc=5","date":"2025-05-21","type":"trial","source":"prnewswire.com","summary":"Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis - prnewsw","headline":"Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxONGE5N0l5OXEwdFBueWlsUkN0bzlpd2cyX1VxbjdwZEloejZtUzlRVHBXRk1PWHE2YVUtTXRXOE5YbFJnUlhQWWMzRWtaeHNHS2F2ZEZxNnktYjZDcGdCaUk3WEJyX1ZqeEtMUVJQbW5SLW9qX09YdnRLbjNRclFiMjRIWVE2d0tWU0o0WGZzb1dPMkZpNUFtSDRQQlB5Rlk?oc=5","date":"2024-10-02","type":"pipeline","source":"BioPharma Dive","summary":"With $115M more, Triveni accelerates immune drug work - BioPharma Dive","headline":"With $115M more, Triveni accelerates immune drug work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOeHhFZmZuR0xPN0thNFAxbElLY19Xb3hsNFFuTzZsSmtLZVppNWF6SFRCaVFreUhrbTFpeUFYMlN0M1RVY2dvNXMxQUFRYTJYVUluOUdFUGlFaXFEaHlDYy1uVndtRjZKSFNkSWlfWVVmRWx5MWJXRmFZZGtvelJoakxQWmJBNHBjdmNLblc4cGdkN3ZXZ1JMY2Jodm5Cdw?oc=5","date":"2024-10-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Triveni scores $115m to expand immunology pipeline - Pharmaceutical Technology","headline":"Triveni scores $115m to expand immunology pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPak5XRTA4dDBVV1ZablZEYU9SSXhuNDVkclBPVEowMG9ibDBCM0dKektLdFQwVG5MRnRQN0thSFljaFdSczlEbk5DN1VmaWZhU2hsQ0hZMXFSZEhQdVJxekdtNGdqejNTaUtsNTd2WEliODlmcGF2amRtMTJRR3VPSk05N1hVUzVsQktBZnNPcw?oc=5","date":"2024-10-02","type":"pipeline","source":"Fierce Biotech","summary":"Triveni ropes in $115M series B less than a year after $92M fundraise - Fierce Biotech","headline":"Triveni ropes in $115M series B less than a year after $92M fundraise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNMUR3QjF2T1lmOHBTODVVc3hmOC1aUDh5eFNSMlU4SWlwcnhaQUNrQmNoWF9GelptNlVoN3ItZndHSkt3dlA4ek5Xd0tDMWlhZHBsOG91ckNGdjMtM2VFMHpsZ2JpenlnbXNLX3ZsdGY3WUZaNlNOcHlPTFUyRlByclhvNEl6Qk4xYnVfZGJySWJrbkxoQTJmNm5NbXo1MDNTUkNpVE5rMVMwM2xtdkd2X2xR?oc=5","date":"2024-06-12","type":"pipeline","source":"citybiz","summary":"Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer - citybiz","headline":"Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPaFpFdUk1OEZoY01QUThkLTZ3dTBHSmNDejVlLUptM0I2S3ptR1NJbUJnN0tXMHdNZVZCaGd5SzlKdnFHazV1Zl9qWUk5cjVWcjVlZ1BUQUo3NVQzazZOUzZvS3BzSGQ1bG8yOFpkTGZGcG9PUjAxalNDOXl1alM5QU9EenRPSXVjaGcyVE9RTUpGdw?oc=5","date":"2023-10-26","type":"deal","source":"BioPharma Dive","summary":"Triveni emerges from biotech merger with $92M for immune disease drugs - BioPharma Dive","headline":"Triveni emerges from biotech merger with $92M for immune disease drugs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}